Back to our people page Back to Locations Back to Back to Article

Dr. Ulrica Sehlstedt

Managing Partner

Board of directors

Global Practice Leader, Healthcare & Life Sciences

Ulrica brings over 20 years of broad-sector experience to serving clients across the entire healthcare and life science ecosystem.

Areas of Focus

Education

Stockholm University
PhD Biophysics
Chalmers University of Technology
M.Sc. Chemical Engineering

Past Experience

LightUp Technologies AB
CEO

Ulrica is a Partner in Arthur D. Little’s Stockholm office and heads the Global Healthcare and Life Sciences Practice.

Her work includes strategy development, opportunity assessment, complex procurement, operational & commercial due diligence, change management, and program management, for healthcare suppliers (pharma, Medtech, and biotech companies), providers (public and private), and investors.

Ulrica is passionate about the role of life science research and development as a lever for prosperity and health. 

Before joining Arthur D. Little in 2007, Ulrica spent seven years as CEO of a molecular diagnostics start-up. She has also been a member of the Swedish Research Council’s Scientific Council for Medicine for six years, and served as a Member of the 2007 and 2016 national expert panels in Life Science Technologies for Future Research Leaders, a program launched by the Swedish Foundation for Strategic Research. 

The brave new world of synthetic biology
Healthcare & life sciences
The brave new world of synthetic biology
Find out more
Time to renew your pilot’s license?
Time to renew your pilot’s license?
Find out more
Tomorrow’s life sciences
Healthcare & life sciences
Tomorrow’s life sciences
Dr. Ulrica Sehlstedt, Dr. Franziska Thomas
Find out more
Healthcare & life sciences
Hyper-collaboration in the healthcare and life science industry – The new imperative
Dr. Franziska Thomas, Ben van der Schaaf, Dr. Ulrica Sehlstedt
The COVID-19 pandemic demonstrated the ability of the healthcare and life science industry to respond to unexpected needs with unprecedented speed. However, independent of the pandemic, the industry was already facing transformation in light of multiple, highly disruptive innovations not only in the traditional field of drug modalities but also in related fields such as digital, AI, data, and medical devices.
Find out more
Healthcare & life sciences
Now is the time for healthcare providers to get into IoT
Dr. Ulrica Sehlstedt, Rebecka Axelsson Wadman, Sean McDevitt, Agron Lasku
Find out more
Transforming healthcare – How curative therapies will disrupt the market
Craig Wylie, Rebecka Axelsson Wadman, Vikas Kharbanda, Dr. Ulrica Sehlstedt
The shift to curative treatments promises to transform the entire healthcare ecosystem. Patients whose conditions were previously managed through ongoing, long-term medication can now be cured through specific courses of treatment. This transforms their lives – but, as this article explains, it also has a disruptive effect on the wider market, shifting payers’ expenditure, increasing the importance of first-mover advantage for pharmaceutical companies, and changing care models for healthcare providers.
Find out more
Healthcare & life sciences
Transforming medical technology businesses to create value with digital
Dr. Ulrica Sehlstedt
There is significant value to be captured with digital products and services in the healthcare industry. However, existing medical technology companies going digital will require major business and operational model changes. This article introduces a framework and set of levers that can help medical technology executives proactively manage these changes and their impact, therefore guiding their companies through digital transformation.
Find out more
Healthcare & life sciences
The Future of Healthcare
François Deneux, Dr. Ulrica Sehlstedt
Unprecedented changes are ahead of us: artificial intelligence, the internet of things, big data, and social and commercial networks are radically changing the way we live and do business, and the impact of these changes will go above and beyond the 1990s experiments with the “dot-com” wave.
Find out more
Healthcare & life sciences
Building the Smart Hospital Agenda
Vikas Kharbanda, Dr. Ulrica Sehlstedt, Johan Treutiger
A number of factors have been contributing to a rapid change in care delivery models world-wide. Increasing cost of care, need to improve access to care, inherent complexity in treatment options and increasing involvement of patients in the care delivery cycles - all of these factors have fostered an environment where hospitals or other care delivery institutions have started shifting focus from treating episodes to managing overall health of patients, while focusing on overall value of care rather than efficiency.
Find out more
Healthcare & life sciences
Digital Pharma - Responding to Challenges and Opportunities from Outside
Dr. Ulrica Sehlstedt
Innovation has always been one of the foundations for success in the pharmaceutical industry. While the sector has been very good at developing innovation from scratch or incremental innovation of existing products, it now faces an ultimately different challenge ╨ dealing with disruptive innovation that is driven by inventions outside the healthcare sector.
Find out more
The Change Side of Transformation - A Wolf in Sheep’s Clothing?
Ralf Baron, Michael Zintel, Dr. Ulrica Sehlstedt
In the new era of "Hypercompetition", companies increasingly need to be agile enough to reinvent and transform themselves. In this article the authors take a closer look at transformation, focusing on the human or change management aspects which are widely recognized as the key obstacles to success.
Find out more

Ulrica is a Partner in Arthur D. Little’s Stockholm office and heads the Global Healthcare and Life Sciences Practice.

Her work includes strategy development, opportunity assessment, complex procurement, operational & commercial due diligence, change management, and program management, for healthcare suppliers (pharma, Medtech, and biotech companies), providers (public and private), and investors.

Ulrica is passionate about the role of life science research and development as a lever for prosperity and health. 

Before joining Arthur D. Little in 2007, Ulrica spent seven years as CEO of a molecular diagnostics start-up. She has also been a member of the Swedish Research Council’s Scientific Council for Medicine for six years, and served as a Member of the 2007 and 2016 national expert panels in Life Science Technologies for Future Research Leaders, a program launched by the Swedish Foundation for Strategic Research. 

The brave new world of synthetic biology
Healthcare & life sciences
The brave new world of synthetic biology
Find out more
Time to renew your pilot’s license?
Time to renew your pilot’s license?
Find out more
Tomorrow’s life sciences
Healthcare & life sciences
Tomorrow’s life sciences
Dr. Ulrica Sehlstedt, Dr. Franziska Thomas
Find out more
Healthcare & life sciences
Hyper-collaboration in the healthcare and life science industry – The new imperative
Dr. Franziska Thomas, Ben van der Schaaf, Dr. Ulrica Sehlstedt
The COVID-19 pandemic demonstrated the ability of the healthcare and life science industry to respond to unexpected needs with unprecedented speed. However, independent of the pandemic, the industry was already facing transformation in light of multiple, highly disruptive innovations not only in the traditional field of drug modalities but also in related fields such as digital, AI, data, and medical devices.
Find out more
Healthcare & life sciences
Now is the time for healthcare providers to get into IoT
Dr. Ulrica Sehlstedt, Rebecka Axelsson Wadman, Sean McDevitt, Agron Lasku
Find out more
Transforming healthcare – How curative therapies will disrupt the market
Craig Wylie, Rebecka Axelsson Wadman, Vikas Kharbanda, Dr. Ulrica Sehlstedt
The shift to curative treatments promises to transform the entire healthcare ecosystem. Patients whose conditions were previously managed through ongoing, long-term medication can now be cured through specific courses of treatment. This transforms their lives – but, as this article explains, it also has a disruptive effect on the wider market, shifting payers’ expenditure, increasing the importance of first-mover advantage for pharmaceutical companies, and changing care models for healthcare providers.
Find out more
Healthcare & life sciences
Transforming medical technology businesses to create value with digital
Dr. Ulrica Sehlstedt
There is significant value to be captured with digital products and services in the healthcare industry. However, existing medical technology companies going digital will require major business and operational model changes. This article introduces a framework and set of levers that can help medical technology executives proactively manage these changes and their impact, therefore guiding their companies through digital transformation.
Find out more
Healthcare & life sciences
The Future of Healthcare
François Deneux, Dr. Ulrica Sehlstedt
Unprecedented changes are ahead of us: artificial intelligence, the internet of things, big data, and social and commercial networks are radically changing the way we live and do business, and the impact of these changes will go above and beyond the 1990s experiments with the “dot-com” wave.
Find out more
Healthcare & life sciences
Building the Smart Hospital Agenda
Vikas Kharbanda, Dr. Ulrica Sehlstedt, Johan Treutiger
A number of factors have been contributing to a rapid change in care delivery models world-wide. Increasing cost of care, need to improve access to care, inherent complexity in treatment options and increasing involvement of patients in the care delivery cycles - all of these factors have fostered an environment where hospitals or other care delivery institutions have started shifting focus from treating episodes to managing overall health of patients, while focusing on overall value of care rather than efficiency.
Find out more
Healthcare & life sciences
Digital Pharma - Responding to Challenges and Opportunities from Outside
Dr. Ulrica Sehlstedt
Innovation has always been one of the foundations for success in the pharmaceutical industry. While the sector has been very good at developing innovation from scratch or incremental innovation of existing products, it now faces an ultimately different challenge ╨ dealing with disruptive innovation that is driven by inventions outside the healthcare sector.
Find out more
The Change Side of Transformation - A Wolf in Sheep’s Clothing?
Ralf Baron, Michael Zintel, Dr. Ulrica Sehlstedt
In the new era of "Hypercompetition", companies increasingly need to be agile enough to reinvent and transform themselves. In this article the authors take a closer look at transformation, focusing on the human or change management aspects which are widely recognized as the key obstacles to success.
Find out more

More About Ulrica
  • Stockholm University
    PhD Biophysics
  • Chalmers University of Technology
    M.Sc. Chemical Engineering
  • LightUp Technologies AB
    CEO